This followed the announcement of broadly based sales growth in the third quarter with Group turnover up 1%.
Core operating profit was up 11% and core earnings per share was up 16% at 28.9p.
The increase in core operating profit was driven by continued strong cost control, including a reduction in R&D expenditure, and the delivery of a further benefit from a programme of initiatives started last year to re-shape and reduce certain long-term operating expenses.
By the end of the third quarter GSK had repurchased Â£1bn of shares and continues to target share repurchases of Â£1-2bn by the end of the year.
At 12:47pm: [LON:GSK] GlaxoSmithKline share price was -6.25p at 1594.75p
Story provided by StockMarketWire.com